Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAS0421a · 1 trial · 1 indication
Apneas and hypopneas per hour (3% desat and/or arousal), % change from baseline
| Arm | Type | Description |
|---|---|---|
| SAS0421a, SAS0421b and SAS0421c | EXPERIMENTAL | Participants will take SAS0421a, SAS0421b and SAS0421c for 3 days. Half doses will be given on the first night. |
| SAS0421a and SAS0421b | ACTIVE_COMPARATOR | Participants will take SAS0421a and SAS0421b for 3 days. Half doses will be given on the first night. |
| SAS0421c | ACTIVE_COMPARATOR | Participants will take SAS0421c for 3 days. Half doses will be given on the first night. |
| Placebo | PLACEBO_COMPARATOR | Participants will take placebos for 3 days. |
| Name | Type | Description |
|---|---|---|
| SAS0421a | DRUG | treatment will be given for 3 days |
| SAS0421b | DRUG | treatment will be given for 3 days |
| SAS0421c | DRUG | treatment will be given for 3 days |
| placebo | DRUG | placebo will be given for 3 days |
Inclusion criteria: * Ages 18 - 79 years * Suspected or diagnosed OSA Exclusion criteria: * Any uncontrolled medical condition * Current use of the medications under investigation * Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, doxapram, almitri...